Programming

BCVS Scientific Sessions 2020

Basic Cardiovascular Science Scientific Sessions
Emerging Opportunities in Cardiovascular Diseases

July 27–30, 2020
Now a Virtual Event
Virtual Livestream
This is where you will find the link to watch live starting July 27.

 



About this Meeting

The 15th annual BCVS 2020 Scientific Sessions has become the premier conference for molecular cardiovascular biology and disease. Sponsored by the American Heart Association Basic Cardiovascular Sciences Council, the world’s leading organization of cardiovascular scientists, the conference attracts leading researchers in fields such as microRNAs, cardiac gene and cell therapy, cardiac development and most recently tissue engineering and iPS cells.

The planned agenda includes 15 fast-paced sessions during 3½ days, set in a forum that promotes the relaxed exchange and discussion of cutting edge research in molecular and translational cardiovascular biology and disease. The program includes a diversity of speakers representing the best cardiovascular scientists from around the world.

In addition, the symposium will be of great value to scientists and executives of pharmaceutical companies and biotechnology firms who are in the cardiovascular space.

Preliminary Program

Below you'll find the session times. For more details on some presentations, see the BCVS 2020 Preliminary Program (PDF).

Click on a day/date to expand or contract

BCVS Preliminary Program - Monday 7.27
Time
(all times are Central)
Activity
12:30 p.m. - 1:00 p.m.BCVS 2020 Opening welcome
Mitch Elkind, MD, AHA President, New York, New York
Elizabeth McNally, MD, PHD, BCVS Council Chair, Chicago, Illinois
1:00 p.m. - 2:00 p.m.Concurrent Session 1A: Beyond the Heart: Systemic Effects of Pathogenic Cardiac Remodeling
Moderator: Gregory Aubert, MD, Chicago, Illiniois

Concurrent Session 1B: Cutting-edge Approaches to Targeting Complex Cardiomyopathies
Moderator: Jil Tardiff, MD, PhD, Tucson, Arizona
2:00 p.m. -  3:00 p.m..Moderated Poster Session 1A: Sarcomeric Function & Contractility
Poster Professor: Danish Sayed, PhD, Newark, New Jersey

Moderated Poster Session 1B: Ion Channels and Arrhythmias
Poster Professor: Ravi Shah, MD, Boston, Massachusetts
3:00 p.m. - 4:00 p.m.Concurrent Session 2A: Cardiovascular Risk Factors-Nicotine Use, Diet and Physical Activities as Modulators
Moderator: Loren Wold, PhD, Columbus Ohio

Concurrent Session 2B: Covid-19 and Cardiovascular Disease
Moderator: Mina Chung, MD, Cleveland, Ohio
4:00 p.m. - 5:00 p.m.

ACS Japanese: Inflammation and Cardiac Remodeling in Heart Failure
Moderator: Junichi Sadoshima, MD, Newark, New Jersey

ACS Korean: Cellular and Molecular Mechanisms of Heart Failure
Moderator: Young-sup Yoon, MD, Atlanta, Georgia

BCVS Preliminary Program - Tuesday 7.28
Time
(all times are Central)
Activity
10:00 a.m. - 11:00 a.m.

Concurrent Session 3A: Molecular Predictors & Markers of Heart Failure Progression
Moderator: Kristine Deleon-Pennell, PhD, Charleston, South Carolina

Concurrent Session 3B: Cardiac Effects of Oxidation and Inflammation
Moderator: Ameen Ismahil, PhD, Birmingham, Alabama

11:00 a.m. - 12:00 p.m.

Concurrent Session 4A: Apoptosis, Necrosis and Autophagy in Heart Disease
Moderator: Asa Gustafsson, PhD, La Jolla, California

Concurrent Session 4B: Novel Pathogenic Pathways in Cardiac Remodeling: Early vs. Late
Moderator: John Calvert, PhD, Suwanee, Georgia

12:00 p.m. - 1:00 p.m.General Session 5: Keynote Lecture - All is in Flux: Cardiac Metabolism in Transition
Moderator: Ivor Benjamin, MD, Milwaukee, Wisconsin
Speaker:  Heinrich Taegtmeyer, MD, Houston, Texas
1:30 p.m. - 2:30 p.m.

Early Career Session: Amplify the Signal, Not the Noise
Moderator: Priscila Sato, PhD, Philadelphia, Pennsylvania

ACS SAHA: Research Advances to Treat Heart Failure
Moderator: Sathyamangla Naga Prasad, PhD, Cleveland, Ohio

2:30 p.m. - 3:30 p.m.

Moderated Poster Session 2A: Myocardial Ischemia, Oxidative Stress and Cardioprotection
Poster Professor: Jean Bopassa, PhD, UTHealth, San Antonio, Texas


Moderated Poster Session 2B: Signal Transduction Pathways
Poster Professor: Joan Heller Brown, PhD, La Jolla, California

3:30 p.m. - 4:30 p.m.

Concurrent Session 6A: Harnessing Precision Medicine to Treat Cardiovascular Disease
Moderator: Renzhi Han, PhD, Columbus, Ohio

Concurrent Session 6B: Novel Animal Models and Translational Insights
Moderator: Martin Petroff, PhD, La Plata, Argentina

BCVS Preliminary Program - Wednesday 7.29
Time
(all times are Central)
Activity
10:00 a.m. - 11:00 a.m.

Concurrent Session 7A: HfpEF in Metabolic Diseases
Moderator: Jonathan Kirk, Maywood, Illinois

Concurrent Session 7B: Cardiotoxicity of Cancer Therapeutics: Mechanisms and Potential Therapies
Moderator: Richard Becker, MD, Cincinnati, Ohio

11:00 a.m. - 12:00 p.m.

General Session 8: Molecular Mechanisms of Cardiac Hypertrophy (BCVS-HFA Joint Session)
Moderator: Rebekah Gundry, PhD, Omaha, Nebraska

Workshop 1 -- Nailing Your Statistics: Rigorous Analysis for Grants & Papers
(Hosted by Circulation Research)
Moderator: Jane Freedman, MD, Worchester, Massachusetts

12:30 p.m. - 1:30 p.m.

General Session 9A: Outstanding Early Career Investigator Award Competition
Moderator: Hesham Sadek, MD, PhD, Dallas, Texas

General Session 9B: Metabolism and Redox Mechanisms in Heart Failure
Moderator: Mahesh Gupta, PHD, Chicago, Illinois

1:30 p.m. - 2:30 p.m.

General Session 10: Women in Science: Go for It (AHA Zoom)
Moderator: Rong Tian, MD, Seattle, Washington

ACS ACRE: Critical Signaling Pathways in Heart Failure
Moderator: Faqian Li, MD, Minneapolis, Minnesota

2:30 p.m. - 3:30 p.m.

Moderated Poster Session 3A: Systems Approach to Cardiovascular Biology
Poster Professor: Young-sup Yoon, MD, Atlanta, Georgia

Moderated Poster Session 3B: Inflammation and the Cardiovascular System
Poster Professor: Beata Wolska, PhD, Chicago, Illinois

3:30 p.m. - 4:30 p.m.

Concurrent Session 11A: Molecular & Cellular Therapy for Heart Failure
Moderator: Li Qian, PhD, Chapel Hill, North Carolina

Concurrent Session 11B: Diastolic & Contractile Dysfunction in Heart Failure
Moderator: John Ralphe, MD, Madison, Wisconsin

4:30 p.m. - 5:30 p.m.

General Session 12: Genomic, Genetic and Epigenetic Mechanism of Heart Failure
Moderator: Susan Cheng, MD, Los Angeles, California

Workshop 2: The Practice of Biomedical Research: Honesty Transparency and Early Career Funding Opportunities
Moderator: Leslie Leinwand, PhD, Boulder, Colorado

BCVS Preliminary Program - Thursday 7.30
Time
(all times are Central)
Activity
10:00 a.m. - 11:00 a.m.

Concurrent Session 13A: Extracellular Matrix; Fibroblasts and More
Moderator: Onur Kanisicak, PhD, Cincinnati, Ohio

Concurrent Session 13B: Regulation of Small RNAs in Heart Failure
Moderator: Jaunian Chen, PhD, Los Angeles, California

11:00 a.m. - 12:00 p.m.

Concurrent Session 14A: Cardiac Arrhythmias: from Basic Mechanisms to Precision Medicine
Moderator: Steven Houser, PhD, Philadelphia, Pennsylvania

Concurrent Session 14B: Systems Approaches to Cardiac Disease: Novel Mechanisms
Moderator: Chengxue Qin, DPhil, Melbourne, Australia

12:00 p.m. - 1:00 p.m.

Moderated Poster Session 4A: Clinical/Translational Research
Poster Professor: Glenn Rowe, PhD, Birmingham, Alabama

Moderated Poster Session 4B: Genetics and Genomics of Cardiovascular Disease
Poster Professor: Sarah Schumacher, PhD, Cleveland, Ohio

1:00 p.m.Conference adjourns

Target Audience

  • Basic cardiovascular scientists
  • Molecular/cellular biologists
  • Physiologists
  • Translational investigators
  • Clinical trialists
  • Practicing cardiologists
  • Cardiovascular nurses and pharmacists

Learning Objectives

At the conclusion of the conference, participants will be able to:
  1. Discuss the latest research on cardiac metabolism and their implications for clinical practice.
  2. Identify critical areas of research and research gaps in heart failure.
  3. Describe current knowledge gaps in research and understanding of the cardiopulmonary effects of e-cigarette use.
  4. Describe opportunities to bring a greater emphasis on translational research to your work.
  1. Discuss the cardiovascular effects of traditional, targeted, and immunological therapies for cancer patients and on their role in the management and prevention of these conditions.
  2. Describe the potential role of and challenges involved in the use of big data analytics to precision medicine to guide cardiovascular research and patient care, and their implications for your work.